 The market is pricing in an approximately 6 chance of FDA approval for Cassava Sciences Alzheimers small molecule pill, Simufilam. The distribution of 147,000 Simufilam to more than 250 Alzheimers patients in at least 16 investigator sites shows zero drug-related serious adverse events vs. 69 occurrence of ARIA with Biogen. 